Business Context and Reporting Period
Company: Achieve Life Sciences, Inc. (ACHV)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2026
Event: Entry into an Open Market Sale Agreement (ATM Program) with Jefferies LLC.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a new capital raising facility:
- Maximum Offering Size: Up to $150.0 million in aggregate offering price.
- Security Type: Common Stock, par value $0.001 per share.
- Sales Agent Compensation: Up to 3.0% of aggregate gross proceeds.
- Underlying Registration: Form S-3 filed on January 23, 2026.
Material Changes
The material change reported is the establishment of an "at-the-market" (ATM) equity offering program. This provides the Company with the flexibility to sell shares from time to time at its sole discretion, subject to market conditions and customary parameters. The Company retains the right to suspend or terminate the program at any time.
Guidance, Outlook, and Use of Proceeds
Management has outlined the intended use of net proceeds from the ATM Program as follows:
- Commercialization of cytisinicline.
- Funding a Phase 3 clinical trial for cytisinicline for e-cigarette cessation.
- Working capital and general corporate purposes.
Risks and Contingencies: The filing notes that the Company has no obligation to sell any shares under the agreement. The program is subject to termination by either party or upon the sale of the maximum program amount.
Investor Verification Checklist
- Verify the current market price of ACHV common stock to assess potential dilution impact.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses and indemnification terms.
- Confirm the status of the cytisinicline Phase 3 clinical trial and commercialization timeline.
- Monitor subsequent filings for actual share sales and proceeds generated under the ATM Program.